Cibc World Markets Corp Invests $361,000 in ADMA Biologics, Inc. (NASDAQ:ADMA)

Cibc World Markets Corp acquired a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA) in the fourth quarter, Holdings Channel reports. The institutional investor acquired 21,076 shares of the biotechnology company’s stock, valued at approximately $361,000.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Larson Financial Group LLC acquired a new position in shares of ADMA Biologics during the 3rd quarter worth about $31,000. GAMMA Investing LLC boosted its stake in ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 967 shares during the last quarter. National Bank of Canada FI acquired a new position in ADMA Biologics during the third quarter valued at approximately $35,000. Vision Financial Markets LLC bought a new stake in ADMA Biologics in the fourth quarter valued at approximately $51,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in ADMA Biologics in the third quarter worth $62,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Price Performance

NASDAQ ADMA opened at $20.32 on Tuesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a 52-week low of $5.90 and a 52-week high of $23.64. The business has a 50 day simple moving average of $16.84 and a 200 day simple moving average of $18.07. The stock has a market cap of $4.80 billion, a price-to-earnings ratio of 72.57 and a beta of 0.60.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.